Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

NCT ID: NCT04531033

Last Updated: 2024-05-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-25
• Study Completion Date: 2022-11-14

Brief Summary

The purpose of this study is to determine if twice or three times daily supplementation of Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day) lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and safety compared to a placebo.

Detailed Description

Participants will be included and/or excluded in the study based on the criteria below:

Inclusion Criteria

• Participants will be male or female between the ages of 18-55 years;
• Participants will be apparently healthy and free from disease, as determined by a health history questionnaire;
• Participants will not be excluded if he or she has been clinically diagnosed with a carbohydrate malabsorption disorder, or is or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other dairy-containing products, or regularly consumes Lactase enzymes for digestive support;
• Participant agrees and can comply with the study protocol;
• Participant provides signed and dated informed consent to participate in the study.

Subject Exclusion Criteria

• Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding;
• Participant is insulin-dependent or -independent diabetic.
• Participant currently uses, or has discontinued the use of nicotine-containing products within twelve (12) months of the start of the study;
• Participant lives or works within an environment that chronically exposes the subject to second-hand smoke;
• Participant currently uses, or has discontinued the use of recreational drugs or medicinal marijuana within twelve (12) months of the start of the study;
• Participant has been clinically diagnosed with a digestive disorder such as gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or other gastrointestinal surgery within twelve (12) months of the start of the study;
• Participant is taking, or has taken antibiotic medications within two (2) weeks of the start of the study;
• Participant has undergone a colonoscopy within two (2) weeks of the start of the study, or is scheduled to receive a colonoscopy during the study;
• Participant has undergone a barium study or received an enema within two (2) weeks of the start of the study, or is scheduled to, or receives such during the study;
• Participant is taking, or has taken probiotics within two (2) weeks of the start of the study;
• Participant uses lactose digesting enzymes during the study;
• Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative / stool softener dietary supplements, over-the-counter, or prescription medications within two (2) weeks of the start of the study;
• Participant is allergic to any ingredient present within the dietary supplement or placebo treatment;
• Participant reports any unusual adverse events associated with this study that, in consultation with the study investigators or the participant's doctor recommends removal from the body;
• Participant fails to comply with the study protocol.

Intervention Below is an overview of the study, including the phases, timepoints, and dependent variables that will be assessed. The total study duration for each subject is approximately fifteen (15) weeks - one (1) week of pre-test familiarization plus fourteen (14) weeks of intervention and testing. Subject testing will commence on a rolling enrollment basis (i.e., all subjects will not start, be tested on, and end the study at the same time).

24 hrs - 12 hrs: Restricted Diet

Discontinue eating:

• All grains (including pasta, bread, cereals)
• Fruits
• Vegetables (including any food products that contain corn, corn starch, etc)
• Nuts and seeds
• Beans/ Legumes
• All dairy products (including cheese, ice cream, butter, and yogurt)
• All meats [except those approved (below)]

Allowed foods:

• Baked or broiled chicken, fish or turkey (salt and pepper seasoning only)
• Plain, steamed white rice
• Eggs
• Clear chicken or beef broth
• White bread (only)
• Participants may drink water, coffee, or tea; no sugar or artificial sweetener; no creamer/cream 12 hrs - 0 hrs: Fasting
• Water only
• No sleeping or vigorous exercise for at least (1) hour prior to any time during the breath test

TIMELINE:

Day -7 - 0 - Pre-screening & Familiarization

• Subjects complete one-week nutrition log via MyFitnessPal Day 0 - Baseline & Acute Response (Lab Test #1; LT1)
• Subject arrives 12-hr fasted (water only) and having followed the 24hr pre-test and lifestyle protocol -> Body Mass (BM) and Hydration (urine) measurements -> 5-minute seated -> Heartrate (HR) and Blood Pressure (BP) measurements -> Gastrointestinal Symptom Score -> Venous Blood collection -> Non-Alcohol Mouth Rinse -> Breath Analysis -> Treatment Dose Consumed with 8-10 fl. oz. H2O -> 30- minute seated -> 25-gram Lactose Challenge/Ingestion -> 60- minute seated -> Non-Alcohol Mouth Rinse -> Breath Analysis -> 60-minute seated -> Non-Alcohol Mouth Rinse -> Breath Analysis -> 60 minute seated -> Gastrointestinal Symptoms Score -> Non-Alcohol Mouth Rinse -> Breath Analysis Day 1 - Day 7 - Treatment Phase
• Subjects consume three (3) servings per day of treatment at scheduled times and conditions for three (3) days -> On Day 4 subjects perform a Lactose Challenge / Ingestion Test at home after a12-hr fast (water only); Gastrointestinal Symptoms Score is collected prior to, and at 180 minutes postprandial (after lactose ingestion) -> Subjects continue to consume three (3) servings per day of treatment at scheduled times and conditions for three (3) days
• Subjects complete one-week nutrition log Day 7 - Subacute Response (Lab Test #2; LT2)
• Repeat LT1
• Subjects discontinue treatment Day 8 - Day 37 - 30- Day Post Treatment Phase
• Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms Scoring
• Subjects complete one-week nutrition logs Day 37 - 30-Day Post Treatment Response (Lab Test #3; LT3)
• Repeat LT1/LT2 testing (less the Treatment Dose + 30-minute seating pre-Lactose Challenge / Ingestion) Day 38 - Day 67 - 60-Day Post Treatment Phase
• Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms scoring
• Subjects complete one-week nutrition logs Day 67 - 60- Day Post Treatment Response (Lab Test #4; LT4)
• Repeat LT1/LT2/LT3 testing (less treatment Dose + 30-minute seated pre- Lactose Challenge/Ingestion) Day 68 - Day 97 - 90-Day Treatment Phase
• Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms Scoring
• Subjects complete one-week nutrition logs Day 97 - 90-Day Post Treatment Response (Lab Test #5; LT5)
• Repeat LT1/LT2/LT3/LT4/ testing (less Treatment Dose + 30- minute seating pre- Lactose Challenge/ Ingestion)

Conditions

Lactose Intolerance

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

placebo made to match dietary supplement being tested.

Low dose 10 billion CFU per day

Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.

Group Type: EXPERIMENTAL

Lactobacillus acidophilus MPH734

Intervention Type: DIETARY_SUPPLEMENT

After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.

High dose 15 billion CFU per day

Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.

Group Type: EXPERIMENTAL

Lactobacillus acidophilus MPH734

Intervention Type: DIETARY_SUPPLEMENT

After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.

Interventions

Lactobacillus acidophilus MPH734

After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

placebo made to match dietary supplement being tested.

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

Lacto-FreedomTM, or LF

Eligibility Criteria

Inclusion Criteria

• Participants will be male or female between the ages of 18-55 years;
• Participants will be apparently healthy and free from disease, as determined by a health history questionnaire;
• Participants will not be excluded if he or she has been clinically diagnosed with a carbohydrate malabsorption disorder, or is or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other dairy-containing products, or regularly consumes Lactase enzymes for digestive support;
• Participant agrees and can comply with the study protocol;
• Participant provides signed and dated informed consent to participate in the study.

Exclusion Criteria

• Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding;
• Participant currently uses, or has discontinued the use of nicotine-containing products within twelve (12) months of the start of the study;
• Participant lives or works within an environment that chronically exposes the subject to second-hand smoke;
• Participant currently uses, or has discontinued the use of recreational drugs or medicinal marijuana within twelve (12) months of the start of the study;
• Participant has been clinically diagnosed with a digestive disorder such as gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or over-the-counter medication for such;
• Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or other gastrointestinal surgery within twelve (12) months of the start of the study;
• Participant is taking, or has taken antibiotic medications within two (2) weeks of the start of the study;
• Participant has undergone a colonoscopy within two (2) weeks of the start of the study, or is scheduled to receive a colonoscopy during the study;
• Participant has undergone a barium study or received an enema within two (2) weeks of the start of the study, or is scheduled to, or receives such during the study;
• Participant is taking, or has taken probiotics within two (2) weeks of the start of the study;
• Participant uses lactose digesting enzymes during the study;
• Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative / stool softener dietary supplements, over-the-counter, or prescription medications within two (2) weeks of the start of the study;
• Participant is allergic to any ingredient present within the dietary supplement or placebo treatment;
• Participant reports any unusual adverse events associated with this study that, in consultation with the study investigators or the participant's doctor recommends removal from the study;
• Participant fails to comply with the study protocol.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Manzo Pharmaceuticals

UNKNOWN

Sponsor Role: collaborator

Lemuel W. Taylor IV

OTHER

Sponsor Role: lead

Responsible Party

Lemuel W. Taylor IV

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

University of Mary Hardin-Baylor

Belton, Texas, United States

Countries

United States

Other Identifiers

LF-1

Identifier Type: -

Identifier Source: org_study_id